Company profile
Avalyn Pharma Inc.
NASDAQ:AVLNBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06329401 | phase2 | active_not_recruiting | 2024-04-03 | 2027-06-01 | Avalyn Pharma Inc. | A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis |
| NCT07194382 | phase2 | recruiting | 2026-03-10 | 2026-12-01 | Avalyn Pharma Inc. | AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF |
FDA applications (0)
No records yet.